Crinetics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 290
- Market Cap
- $4.3B
- Website
- http://www.crinetics.com
- Introduction
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03792555
- Locations
- 🇷🇴
National Institute of Endocrinology "C. I. Parhon", Bucharest, Romania
🇵🇱Centrum Nowoczesnch Terapii "Dobry Lekarz", Kraków, Poland
🇸🇰National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03789656
- Locations
- 🇺🇸
Keck Medical Center of USC University of Southern California, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT03276858
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia